2nd ETN School: “Translational drug Research” | Lead: H. Bräuner-Osborne (UCPH) | 15-19.05.2017 | ||
Objectives: Overview on drug discovery and development; CaSR-specific case histories; Basics of imaging mass spectrometry. | Open to external students | ECT: 4.0 | ||
WS: Fundamentals of Drug Discovery and Development: (responsible E.F. Nemeth, K.Seuwen, E. Durchschlag): Day 1 • Identifying a drug target; • Target-based vs phenotypic screening, compound libraries and molecular modelling; • Selecting the clinical candidate; pharmacokinetics; • Primary and secondary pharmacology, toxicology; • Design and performance of clinical trials in conformance with EMEA and GCP guide-lines; Day 2 • Discovery and development of calcimimetics for hyperparathyroidism, second generation calcimimetics; • Calcilytics for osteoporosis; • drug repurposing of calcilytics for rare diseases; • Next generation of calcimimetics. | ||||
Protein Structure-Based Drug Design: (Responsible: F. Bruggeman, L. Pugliese): • Pipeline of drug target selection; • Drug design via protein modelling, drug synthesis, and high-throughput testing; • homology modelling and dynamical behaviour of GPCRs. | ||||
WS: Imaging: (responsible A. Cissoko and R. Ecker) • Imaging mass spectrometry workflow i.e. sample preparation, matrix application, instrumentation, and image and data processing. | ||||
WS: Management Systems: (responsible A. Hollo-Tas) • Evaluation and discussion session summing up what has been learned during the e-Learning Course that preceded it. |
2nd ETN School on Translational Drug Research took place in Copenhagen 15th-19th May 2017.
Prof. Hans Bräuner-Osborne, from the School of Pharmaceutical Sciences at the University of Copenhagen, hosted the 2nd ETN school. "Interesting and high quality lectures on translational drug research have been presented. The format and setting was ideal to interact and share knowledge and most important it allowed the ESRs to establish stronger connections not only as colleagues! I am confident that we are really working as a robust network that can make important progress in the CaSR’s research" (Maria Lo Giudice, ESR at Biotalentum)